HHS Public Access

Author manuscript

ACS Chem Neurosci. Author manuscript; available in PMC 2017 December 05.

Published in final edited form as:

ACS Chem Neurosci. 2017 August 16; 8(8): 1801–1811. doi:10.1021/acschemneuro.7b00200.

Sigma 2 Receptor/Tmem97 Agonists Produce Long Lasting Antineuropathic Pain Effects in Mice

James J. Sahn[†], **Galo L. Mejia**[‡], **Pradipta R. Ray**[‡], **Stephen F. Martin**[*,†,iD], and **Theodore J. Price**[*,‡,iD]

[†]Department of Chemistry and Biochemistry, The University of Texas at Austin, Austin, Texas 78712, United States

[‡]School of Behavioral and Brain Sciences, The University of Texas at Dallas, Richardson, Texas 75080, United States

Abstract

Neuropathic pain is an important medical problem with few effective treatments. The sigma 1 receptor (σ1R) is known to be a potential target for neuropathic pain therapeutics, and antagonists for this receptor are effective in preclinical models and are currently in phase II clinical trials. Conversely, relatively little is known about σ2R, which has recently been identified as transmembrane protein 97 (Tmem97). We generated a series of σ1R and σ2R/Tmem97 agonists and antagonists and tested them for efficacy in the mouse spared nerve injury (SNI) model. In agreement with previous reports, we find that σ1R ligands given intrathecally (IT) produce relief of SNI-induced mechanical hypersensitivity. We also find that the putative σ2R/Tmem97 agonists **DKR-1005, DKR-1051**, and **UKH-1114** (K_i ~ 46 nM) lead to relief of SNI-induced mechanical hypersensitivity, peaking at 48 h after dosing when given IT. This effect is blocked by the putative σ2R/Tmem97 antagonist **SAS-0132**. Systemic administration of **UKH-1114** (10 mg/kg) relieves SNI-induced mechanical hypersensitivity for 48 h with a peak magnitude of effect equivalent to 100 mg/kg gabapentin and without producing any motor impairment. Finally, we find that the *TMEM97* gene is expressed in mouse and human dorsal root ganglion (DRG) including populations of neurons that are involved in pain; however, the gene is also likely expressed in non-neuronal cells that may contribute to the observed behavioral effects. Our results show robust antineuropathic pain effects of σ1R and σ2R/Tmem97 ligands, demonstrate that σ2R/Tmem97 is a novel neuropathic pain target, and identify **UKH-1114** as a lead molecule for further development.

Graphical Abstract

[*]**Corresponding Authors**, Mailing address: University of Texas at Austin, Welch Hall 5.224, 105 E 24th St., Stop A5300, Austin, TX 78712. Telephone: 512-471-3915. sfmartin@mail.utexas.edu. [*]Mailing address: School of Behavioral and Brain Sciences, University of Texas at Dallas, JO 4.212, 800 W. Campbell Rd., Richardson, TX 75080. Telephone: 972-883-4311. Theodore.price@utdallas.edu.

ORCID

Stephen F. Martin: 0000-0002-4639-0695

Theodore J. Price: 0000-0002-6971-6221

Author Contributions

J.J.S. prepared compounds; J.J.S., G.L.M., and P.R.R. performed experiments; J.J.S., P.R.R, S.F.M., and T.J.P. designed experiments; J.J.S., P.R.R., S.F.M., and T.J.P. wrote the paper.

The authors declare no competing financial interest.



Keywords

Neuropathic pain; sigma 1 receptor; sigma 2 receptor; Tmem97; dorsal root ganglion; drug discovery

INTRODUCTION

Neuropathic pain is a common medical problem that is very poorly treated by current therapeutics. Recent meta-analyses show that the most widely prescribed drugs for neuropathic pain only achieve 50% pain relief in 1 of 4 patients for the antidepressants (e.g., monoamine oxidase inhibitors) and are effective in as few as 1 in 7 patients for the gabapentinoids.[1] Better therapeutics are clearly needed for neuropathic pain. Sigma receptors (σRs) are unique transmembrane proteins expressed throughout the CNS (central nervous system) and in certain peripheral tissues. Consisting of two subtypes, the sigma 1 receptor (σ1R) and the sigma 2 receptor (σ2R), these proteins are involved in intracellular ion regulation and neuron survival.[2] σ1R has been cloned and a crystal structure of the receptor obtained.[3] The involvement of this receptor in pain signaling has been studied extensively, and a variety of compounds that bind to σ1R demonstrate antinociceptive effects.[4] E-52862,[5] a σ1R antagonist, is currently in phase II clinical trials for the treatment of neuropathic pain as both a monotherapy and in a multidrug cocktail.

Although strong evidence supports a role for σ1R in neuropathic pain, σ2R has not been explored as a pain target, and the molecular identity of this receptor has been challenging to pinpoint. Molecular cloning recently confirmed the identify of σ2R as transmembrane protein 97 (Tmem97),[6] and this receptor will accordingly be referred to as σ2R/Tmem97 herein unless we are referring to the Tmem97 mouse or TMEM97 human genes. σ2R/Tmem97 is a gene product that appears to be involved in cholesterol trafficking and homeostasis and interacts with NPC-1, a protein responsible for shuttling lipids to postlysosomal locations.[7–9] σ2R/Tmem97 is involved in regulating intracellular Ca^{2+} concentration, and certain σ2R/Tmem97 ligands can induce a transient rise in intracellular Ca^{2+} levels,[2] while other compounds that bind to σ2R/Tmem97 suppress Ca^{2+} influx in the presence of an inducer.[10] Some evidence suggests that compounds that bind to σ2R/Tmem97 modulate a signaling pathway involving progesterone receptor membrane component one (PGRMC1[11]),[10] a heme binding protein[12] involved in cell survival[2] and apoptosis.[13] With respect to medical relevance, it is noteworthy that *TMEM97* has been implicated in the metabolic disorder, Niemann-Pick disease,[9] as well as in multiple neurodegenerative and neurological conditions.[14] Indeed, small molecules that bind to σ2R/Tmem97 are emerging as potential therapeutics for a range of CNS disorders, including Alzheimer's disease (AD)[15] and schizophrenia.[16]

We have discovered that the chlorinated norbenzomorphan and methanobenzazocine scaffolds **1** and **2** (Figure 1) are excellent templates for preparing both selective and mixed affinity σ1R and σ2R/Tmem97 ligands.[17] In the context of CNS lead development, these scaffolds are of particular interest because of their drug-like properties[18,19] and the ease with which they cross the blood brain barrier, as demonstrated by representative compounds **SAS-0132**[10] and **DKR-1051** (Figure 1). In vivo testing has revealed that some compounds derived from **1** and **2** have promising medicinal properties that may warrant further preclinical development. For example, certain σ2R/Tmem97 ligands are neuroprotective[10] and also restore cognitive function in transgenic AD mice[10,20] as well as in aged, nondiseased animals,[10] the latter of which suggests σ2R/Tmem97 may be a potential target for treating mild cognitive impairment (MCI). Despite this increasing knowledge base and the emergence of tool ligands for probing σ2R/Tmem97, the involvement of σ2R/Tmem97 in neuropathic pain has not yet been reported.

Herein we describe the antineuropathic pain properties of a series of σ1R and σ2R/Tmem97 ligands in mice. We report that molecules that bind to σ2R/Tmem97 as putative agonists exert a profound effect on mechanical hypersensitivity in the spared nerve injury (SNI) model with a duration of action and potency that is superior to that of gabapentin. Small molecule modulation of σ2R/Tmem97 may thus represent a new approach for managing pain by a previously unexplored mechanism of action.

RESULTS

Screening of σ1R and σ2R/Tmem97 Ligands for Activity in the Mouse SNI Model

Several previous studies have demonstrated that σ1R antagonists show efficacy in rodent neuropathic pain models via a spinal mechanism of action,[21–23] but the possible effect of σ2R/Tmem97 ligands in this model has not been explored. We screened a series of σ1R and σ2R/Tmem97 ligands (Figure 2) for activity in the SNI model via a single IT injection. We chose this route of administration because σ1R antagonists have been shown to be active in rodent pain models with IT injection,[21,24] and because we had incomplete knowledge of compound disposition in vivo with systemic dosing.

We first assessed the σ1R preferring ligands, **JWG-1014, JSS-1027**, and **MFG-1046**, all given at 10 μg doses, and observed antipain effects for all three compounds that were significantly different from vehicle. **JWG-1014** and **JSS-1027** (Figure 8) both demonstrated efficacy 48 h post IT injection, and this effect persisted through 120 h after ligand administration (Figure 3). Faster onset of action was observed with **MFG-1046** (Figure 9), which elicited an antipain effect at 24 h that continued through 72 h after IT injection (Figure 3).

We then tested four σ2R/Tmem97 preferring ligands of the norbenzomorphan and methanobenzazocine structural class, as well as the known σ2R/Tmem97 agonist, siramesine.[25–27] Siramesine induced a small inhibitory effect on mechanical hypersensitivity that was significant at 24 and 48 h (Figure 4A). On the other hand, **DKR-1005, DKR-1051**, and **UKH-1114** all produced significant antimechanical hypersensitivity effects at either 24 or 48 h after IT injection (Figure 4B).

Based on the observed in vivo effects of the four σ2R/Tmem97 preferring ligands examined, tentative functional activity assignments were made. Compounds **DKR-1005, DKR-1051**, and **UKH-1114** elicited pronounced and sustained antinociceptive effects. However, when **UKH-1114** was administered with **SAS-0132**, the antinociceptive action of **UKH-1114** was abolished (Figure 5). Because **UKH-1114** elicits a significant antipain effect that is completely blocked by **SAS-0132**, we surmise that **UKH-1114** is a σ2R/Tmem97 agonist (or partial agonist) and that σ2R/Tmem97 agonism is responsible for the antimechanical hypersensitivity effects observed with these compounds in SNI mice. On the other hand, **SAS-0132** appears to function as a σ2R/Tmem97 antagonist by suppressing the action of **UKH-1114**. Indeed, these findings are consistent with our previous work that showed that **SAS-0132** behaves as a σ2R/Tmem97 antagonist, whereas **DKR-1051** acts as a σ2R agonist[10] based upon their opposing effects upon Ca^{2+} in SK-N-SH neuroblastoma cells. Namely, treatment of SK-N-SH neuroblastoma cells with **DKR-1051** induces a rapid Ca^{2+} transient, and this effect is attenuated when cells are pretreated with **SAS-0132**.

Systemic Administration of σ2R/Tmem97 Agonist Alleviates Neuropathic Pain

Of the putative σ2R/Tmem97 agonists we tested, **UKH-1114** had the largest behavioral effect, and its chemical properties and high selectivity for σ2R/Tmem97 versus >50 other proteins (See Tables 1 and 2) make it an eligible candidate for systemic dosing.

Therefore, we injected **UKH-1114** IV in mice at 10 mg/kg and compared the effect of the compound to the gold-standard antineuropathic pain treatment, gabapentin (100 mg/kg). Gabapentin completely reversed mechanical hypersensitivity at 1 and 3 h after injection, but animals were fully mechanically hypersensitive again 24 h after IV injection. **UKH-1114** also produced a complete reversal of mechanical hypersensitivity but with a different time course (Figure 6A). A significant effect was observed at both 24 and 48 h after injection indicating that pain relief from this mechanism lasts longer than that produced with a 10-fold larger dose of gabapentin.

Because the mechanism of action of σ2R/Tmem97 ligands for neuropathic pain relief is not known, we were concerned that this effect could be produced by motor impairment. To test this possibility we used the rotorod test. SNI mice were given IV vehicle or **UKH-1114** and tested at the peak time point for alleviation of neuropathic pain, 48 h after injection. There was no effect of **UKH-1114** on motor performance (Figure 6B) ruling out the possibility of motor impairment.

Tmem97 Gene Expression Analysis in Mouse and Human Tissues

To gain insight into where σ2R/Tmem97 is expressed, we quantified Tmem97 mRNA relative abundance in mouse DRG as well as additional tissues, and their orthologous tissues in humans, based on publicly available sequencing data (human data sets: GTex project,[28] ENCODE project,[29] Uhlén et al.,[30] Duff et al.,[31] and the UTD DRG project;[32] mouse data sets: mouse ENCODE project,[33] Rakic et al.,[34] Gerhold et al.,[35] Eipper-Mains et al.,[36] and Huan et al.[37]). We find that *Tmem97* gene expression and its human orthologue (*TMEM97*) are ubiquitously expressed in a wide range of tissues, with higher expression in the human and mouse gastrointestinal (GI) tract commensurate with its role in cholesterol trafficking[7]

(Figure 7A). While expression levels in the human DRG is high, both single cell[38] and bulk[35] RNA-seq for mouse DRGs identify gene expression, but at lower levels than in human (Figure 7A). *TMEM97/Tmem97* is also relatively highly expressed in human and mouse spinal cord. While the detection rate for *Tmem97* across mouse DRG neuronal subpopulations is relatively low, it is clearly expressed in subpopulations of peptidergic and nonpeptidergic nociceptors (Figure 7B). Given the high TPM levels in mouse and human DRG, *Tmem97* may also be expressed in non-neuronal cells in DRG (e.g., satellite glial cells or Schwann cells). Unfortunately, mouse DRG glial transcriptomes have not been characterized, so we turned to a CNS tissue where these cell populations have available transcriptomes. We find that in adult cerebral cortex,[39] Tmem97 expression in cortical glial cells can be enriched 2-fold or more over neuronal expression levels (Figure 7C), lending credence to the hypothesis of glial expression of *Tmem97* in the DRG and/or spinal cord.

DISCUSSION

Several primary conclusions may be reached based upon the work described herein. First, our results using distinct σ1R binding ligands are consistent with previous demonstrations that σ1R antagonists reduce nerve injury-induced mechanical hypersensitivity.[21,40] This observation suggests that the σ1R binding ligands described herein might be antagonists. Second, we find that σ2R/Tmem97 ligands **DKR-1005, DKR-1051**, and **UKH-1114** bind σ2R/Tmem97 with high affinity and produce antinociceptive effects when administered IT to SNI mice. **UKH-1114** is the most efficacious of these compounds in vivo, producing a strong antinociceptive effect when administered IV that was longer lasting and equally efficacious at 1/10 the dose of gabapentin. **UKH-1114** is highly selective for σ2R/Tmem97 binding with an affinity 28-fold greater at σ2R/Tmem97 than at σ1R, and with negligible affinity for 55 other targets (Table 2). While *TMEM97*/*Tmem97* is expressed in DRG and spinal cord of humans and mice, the gene is likely expressed in a mix of neuronal and non-neuronal cells that may include key glial and/or immune cells that are thought to play an important role in the pathogenesis of neuropathic pain.[41] Therefore, we conclude the σ2R/Tmem97 is a promising target for the generation of neuropathic pain drugs.

An interesting aspect of our behavioral findings is the relatively long onset of action of the compounds that we tested compared to rapid onset actions in previous studies with distinct ligands.[21,40,42,43] There could be several reasons for this observation. One is that most previous studies have looked at short time points after administration of σ1R antagonists (30 or 45 min) or at repeated dosing effects[21,40,42,43] so it is possible that effects with a slower onset are missed by these acute dosing schedules but are part of the sustained efficacy observed with repeated dosing. Another possibility is that while the mechanism of action of σ1R antagonists in pain was first thought to involve a spinal mechanism of action,[21–23] more recent studies suggest an action of DRG neurons where σ1R is also expressed.[44] It is therefore probable that the time to onset of effects is due to the time that is needed for the drug to diffuse to sites of action that are more distant from the injection site in the intrathecal space. Because σ1Rs are found on the nuclear envelop of DRG neurons,[44] yet another possibility is that the effect of these compounds is transcriptional. If this were the case, this would also potentially take longer to manifest as a behavioral change. These considerations aside, our results are consistent with previous studies where σ1R antagonists produced long

lasting relief of neuropathic mechanical hypersensitivity when given IT.[21] Another important consideration here is that all of the compounds we examined as σ1R binding ligands also have affinity at σ2R/Tmem97 that could alter their behavioral effects, and some of them have affinity in the low nM range (**JSS-1027** and **MFG-1046**).

To our knowledge, σ2R/Tmem97 ligands have not been previously tested for antinociceptive effects. The σ2R/Tmem97 ligands described herein have high affinity for σ2R/Tmem97, have good specificity relative to σ1R binding, and have little affinity for other targets in a small specificity screen. Indeed, **UKH-1114** displays exceptional selectivity for σ2R/Tmem97 over >50 other receptors and channels. Although the previously described σ2R/Tmem97 agonist, siramesine, produced only a small effect in SNI mice, several other putative σ2R/Tmem97 agonists produced strong effects when given IT in the SNI model. This effect was blocked in the case of **UKH-1114** by the known σ2R/Tmem97 antagonist, **SAS-0132**, strongly implicating σ2R/Tmem97 agonism as the mode of action responsible for antinociception. **UKH-1114** was chosen to test via systemic administration in the SNI model. This compound produced a strong antimechanical hypersensitivity effect that was long lasting and devoid of motor impairment. The peak magnitude of effect was equivalent to the standard of care neuropathic pain drug, gabapentin, but it was much longer lasting at 10-fold lower dose. We observed a relatively long onset to antinociceptive action with putative σ2R/Tmem97 agonists, like σ1R ligands, although this onset to action was shorter when **UKH-1114** was given IV. This may be explained by the expression of the *Tmem97* gene, which is clearly expressed in structures outside of the intrathecal space and has high expression in the DRG and in non-neuronal cells in the DRG and CNS, suggesting the possibility of immune cell expression. We mined publicly available data sets and found that *Tmem97* mRNA is expressed in many mouse and human tissues, but in the mouse CNS, expression levels are apparently higher in many non-neuronal cells types, including astrocytes and microglia. This is consistent with the known expression of *TMEM97* in human glioma cells.[45] While beyond the scope of the present experiments, the discovery of tool ligands to manipulate σ2R/Tmem97 function will allow for testing the role of this receptor in a variety of cell types in the pain pathway.

More work is clearly needed to understand the role of σ2R/Tmem97 in pain, but these unprecedented results provide compelling support for developing σ2R/Tmem97 agonists as a novel strategy for the pharmacological management of neuropathic pain, bringing forth the possibility for patients to experience enhanced pain relief and reduced side-effects by modulating a receptor not targeted by currently approved FDA drugs. We are in the process of identifying other σ2R/Tmem97 agonists to further explore their utility as potential therapeutics for neuropathic pain.

METHODS

Laboratory Animals

All animal procedures were approved by The University of Texas at Dallas Institutional animal care and use committee (IACUC) and were in accordance with National Institutes of Health Guidelines. All of the experiments were performed on male C57Bl6/J mice obtained from Envigo at 4 weeks of age. Mice were housed in the University of Texas at Dallas

Animal Care Facility for at least 1 week prior to the start of behavior testing and surgery. Animals had ad libitum access to food and water and were on a 12 h noninverted light/dark cycle. Experimenters were blinded to treatment groups in behavioral experiments. Sample size was estimated by performing a power calculation using G*Power (version 3.1.9.2). With 80% power, an expectation of $d = 2.2$ effect size in behavioral experiments, and alpha set to 0.05, the sample size required was calculated as $n = 5$ per group. Standard deviation (set at 0.3) for the power calculation was based on previously published mechanical threshold data.[46–48]

Behavioral Testing

Mechanical sensitivity was assessed using stimulation of the hindpaw of the mouse with calibrated von Frey filaments from Stoelting. We used the modified up–down method described previously.[49] Following baseline testing, neuropathic pain was induced in mice using the SNI surgery model. This surgery consists of exposing and cutting the peroneal and tibial branches of the sciatic nerve leaving the sural nerve intact.[50] Two-weeks postsurgery, mechanical sensitivity testing was repeated to ensure that mechanical hypersensitivity had indeed been produced. Following this test, groups of SNI mice were treated with intrathecal (IT) injections[51] of test compounds given in a volume of 5 μL made up in sterile saline and mechanical sensitivity was assessed at time points indicated in figures. Screening for the effect of IT injection of test compounds on SNI-induced mechanical hypersensitivity was done between 21 and 60 days after SNI. Some groups of mice were tested with multiple compounds to reduce the number of animals that were needed for this study. If mice were given multiple injections they were always spaced by at least 14 days between injections. Some animals received a maximum of 3 IT injections but most received 2. In some experiments drugs were given by intravenous (IV) injection through the tail vein in a volume of 100 μL in sterile saline and mechanical sensitivity was assessed at time points indicated in figures. RotoRod testing was done on an automated rotorod device set to accelerate to a final speed of 40 rotations per minute over a 200 s time course. Mice were trained on the rotorod twice and latency to fall was recorded on the third trial.

Chemical Synthesis and Characterization

Toluene was dried by filtration through one column of activated, neutral alumina followed by one column of Q5 reactant[52] and was determined to have less than 50 ppm of H_2O by Karl Fischer coulometric moisture analysis. Acetonitrile (CH_3CN), diethyl ether (Et_2O), ethyl acetate (EtOAc), methanol (MeOH), methylene chloride (CH_2Cl_2), 1,2-dichloroethane (DCE), triethylamine (Et_3N), and diisopropylethylamine (*i*-Pr_2NEt) were used without further purification. All reagents were reagent grade and used without purification unless otherwise noted. All reactions involving air or moisture sensitive reagents or intermediates were performed under an inert atmosphere of nitrogen or argon in glassware that was flame or oven-dried. Reaction temperatures refer to the temperature of the cooling/heating bath. Volatile solvents were removed under reduced pressure using a Buchi rotary evaporator at 20–30 °C (bath temperature). Thin layer chromatography was run on precoated plates of silica gel with a 0.25 mm thickness containing 60F-254 indicator (EMD Millipore). Chromatography was performed using forced flow (flash chromatography) and the indicated solvent system on 230–400 mesh silica gel (Silicycle flash F60) according to the method of

Still and colleagues[53] unless otherwise noted. Radial Preparative Liquid Chromatography (radial plc) was performed on a Chromatotron using glass plates coated with Merck, TLC grade 7749 silica gel with gypsum binder and fluorescent indicator.

Proton nuclear magnetic resonance (^{1}H NMR) and carbon nuclear magnetic resonance (^{13}C NMR) spectra were obtained at the indicated field as solutions in $CDCl_3$ unless otherwise indicated. Chemical shifts are referenced to the deuterated solvent (*e.g.*, for $CDCl_3$, δ = 7.26 ppm and 77.0 ppm for ^{1}H and ^{13}C NMR, respectively) and are reported in parts per million (ppm, δ) relative to tetramethylsilane (TMS, δ = 0.00 ppm). Coupling constants (J) are reported in Hz and the splitting abbreviations used are s, singlet; d, doublet; t, triplet; q, quartet; m, multiplet; comp, overlapping multiplets of magnetically nonequivalent protons; br, broad; app, apparent. Molecular mass was determined using an LCMS system comprised of an Agilent 1200 Series HPLC and an Agilent 6130 single quadrupole mass spectrometer. Samples were injected onto a Phenomenex Gemini C18 column (5 μm, 2.1 × 50 mm) and eluted at 0.7 mL/min using a gradient of 10–90% acetonitrile, 0.1% formic acid (11 min linear ramp). Positive mode electrospray ionization ESI was used to verify the identity of the major component. All compounds submitted for in vivo testing were >95% purity as determined by LC via AUC at 214- and 254 nm. Experimental and characterization data for **1**,[54] **S4, S5, SAS-0132**,[55] and **DKR-1005** have been reported previously, and the preparation of the nor-chloro analogue of **2** has been described.[56]

(±)-2-Phenethyl-2,3,4,5-tetrahydro-1H-1,5-methanobenzo[c]-azepine (JSS-1027)—



1 **JSS-1027**

A mixture of **1** (150 mg, 0.45 mmol) and 10% Pd/C (45 wt %, 60 mg) in ethanol (5 mL) was stirred under an atmosphere of H_2 for 6.5 h. The catalyst was removed by filtration through a cotton plug, and the combined filtrates were concentrated under reduced pressure to provide 71 mg of a light brown oil, which was dissolved in CH_3CN (5 mL). (2-Phenyl)ethyl bromide (**S1**, 0.13 mL, 0.90 mmol) and K_2CO_3 (248 mg, 1.8 mmol) were added, and the mixture was heated at 50 °C for 20 h. The reaction was cooled to room temperature and the solids removed by filtration. The combined filtrates were concentrated to give a yellow oil that was purified using radial plc, eluting with 100% hexanes → 20% EtOAc/hexanes, to give 90 mg (76%) of **JSS-1027** as a light-yellow oil: ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.36–7.30 (m, 3 H), 7.29–7.16 (comp, 6 H), 4.08 (d, J = 5.0 Hz, 1 H), 3.19 (m, 1 H), 2.94 (td, J = 12.5, 5.9 Hz, 1 H), 2.84 (td, J = 10.0, 5.0 Hz, 1 H), 2.77 (dd, J = 15.0, 5.0 Hz, 1 H), 2.65 (td, J = 10.0, 5.0 Hz, 1 H), 2.37 (td, J = 12.5, 5.9 Hz, 1 H), 2.28 (m, 1 H), 2.07 (td, J = 10.0, 5.0 Hz, 1 H), 2.02 (d, J = 10.0 Hz, 1 H), 1.59 (m, 1 H), 1.48 (J = 10.0, 5.0 Hz, 1 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 146.4, 140.5, 138.7, 128.8, 128.4, 127.7, 126.2, 126.1, 124.1, 122.5, 63.7, 58.3,

46.9, 44.5, 39.9, 34.4, 30.2; IR (thin film) 2942, 2811, 1472, 1121 cm^{-1}; HRMS (ESI) *m*/*z* calcd for $C_{19}H_{22}N$ $(M+H)^+$, 264.1747; found, 264.1748.

(±)-2-Methyl-2,3,4,5-tetrahydro-1H-1,5-methanobenzo[c]-azepin-8-yl)morpholine (JWG-1014)—

Iodotrimethylsilane (318 mg, 0.226 mL 1.59 mmol) was added in one portion to a solution of carbamate **S4** (300 mg, 0.797 mmol) in CH_2Cl_2 (12 mL) at 0 °C in a flask wrapped in foil. The cooling bath was removed after 1 h, and the reaction was stirred for an additional 4 h, whereupon the mixture was cooled to 0 °C and methanolic HCl (2.0 M, 5 mL) added. After stirring for 5 min, the volatiles were removed under reduced pressure, 2 N $HCl_{(aq)}$ (20 mL) was added, and the aqueous mixture was extracted with Et_2O (2 × 15 mL). The pH of the aqueous layer was adjusted to ~9 by the slow addition of 2.2 M $NaOH_{(aq)}$ and then extracted with CH_2Cl_2 (3 × 20 mL). The combined organic extracts were dried (Na_2SO_4) and concentrated under reduced pressure to afford 155 mg (79%) of the secondary amine intermediate, which was of sufficient purity (>95% LC and ^1H NMR) to be used in the next step without purification. Paraformaldehyde (S6, 66 mg, 2.2 mmol) was added to a solution of secondary amine (28 mg, 0.11 mmol) in DCE (1 mL) followed by the addition of sodium triacetoxyborohydride (117 mg, 0.55 mmol) and acetic acid (10.5 μL, 0.18 mmol). The mixture was stirred for 24 h and then quenched by the addition of 2.2 M $NaOH_{(aq)}$ (~1 mL) and H_2O (~2 mL). After stirring for 5 more min, the layers were separated, H_2O was added to the aqueous mixture (~2 mL) followed by extraction with CH_2Cl_2 (3 × 20 mL). Brine was added to the aqueous mixture, which was then extracted with CH_2Cl_2 (2 × 20 mL). The combined organic extracts were dried ($MgSO_4$), filtered, and concentrated under reduced pressure to give the *N*-methylamine, which was purified via flash column chromatography (SiO_2), eluting with 100% hexanes → 10% EtOAc/hexanes → 100% EtOAc → 10% MeOH/EtOAc → 20% MeOH/EtOAc to give 26 mg (92%; 73% over two steps) of **JWG-1014** as a light yellow oil: ^1H NMR (500 MHz, $CDCl_3$) δ 7.12 (d, J = 10.0 Hz, 1 H), 6.81 (s, 1 H), 6.80 (d, J = 10.0 Hz, 1 H), 3.88 (t, J = 5.0 Hz, 4 H), 3.83 (d, J = 5.0 Hz, 1 H), 3.15 (t, J = 5.0 Hz, 4 H), 3.11–3.07 (m, 1 H), 2.61 (dd, J = 7.5 Hz, 1 H), 2.22 (s, 3 H), 2.04 (d, J = 10.0 Hz, 1 H), 1.98–1.85 (comp, 3 H), 1.54–1.47 (m, 1 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 150.3, 138.9, 138.1, 123.0, 115.3, 113.0, 67.0, 66.1, 50.2, 48.4, 44.4, 43.2, 38.4, 29.9; IR (thin film) 2935, 2846, 1492, 1245, 1121 cm^{-1}; HRMS (ESI) *m*/*z* calcd for $C_{16}H_{23}N_2O$ $(M+H)^+$, 259.1805; found, 259.1803.

(±)-Benzyl-9-chloro-3,4,5,6-tetrahydro-1,6-methanobenzo[c]-azocine-2(1H)-carboxylate (2).[56]—



2

White solid (crystals from CH_3CN); mp 116–119 °C; ^{1}H NMR (500 MHz, $CDCl_3$, as a mixture of rotamers) δ 7.53 (br s, 0.4 H), 7.40 (d, J = 10.0 Hz, 1 H), 7.34 (t, J = 7.5 Hz, 1 H), 7.30–7.15 (comp, 3.6 H), 7.14–7.07 (m, 1 H), 6.99 (t, J = 7.5 Hz, 1 H), 5.46 (d, J = 7.5 Hz, 0.4 H), 5.29 (d, J = 7.5 Hz, 0.6 H), 5.18 (d, J = 15.0 Hz, 0.6 H), 5.15–5.08 (m, 1 H), 5.01 (d, J = 15.0 Hz, 0.4 H), 4.08 (dd, J = 15.0, 8.8 Hz, 0.6 H), 3.83 (dd, J = 15.0, 8.8 Hz, 0.4 H), 3.33–3.26 (m, 1 H), 3.20–3.07 (m, 1 H), 2.31–2.17 (m, 1 H), 2.08 (t, J = 15.0 Hz, 1 H), 1.78–1.65 (comp, 2 H), 1.53–1.39 (m, 1 H), 0.98–0.85 (m, 1 H); ^{13}C NMR (125 MHz, $CDCl_3$, as a mixture of rotamers) δ 155.6, 155.4, 147.5, 147.3, 145.1, 145.0, 136.8, 136.5, 132.6, 132.4, 128.7, 128.5 (2 C), 128.4, 128.2, 127.9, 127.8, 125.5, 125.1, 124.6, 124.4, 67.5, 67.2, 58.8, 58.2, 44.7, 44.1, 42.9, 42.7, 35.3, 34.9, 34.7, 24.7, 24.5; IR (thin film) 2942, 1705, 1417, 1279 cm^{-1}; HRMS (ESI) m/z calcd for $C_{20}H_{20}ClNNaO_2$ $(M+Na)^+$, 364.1080; found, 364.1084.

(±)-9-Chloro-2-(cyclohexylmethyl)-1,2,3,4,5,6-hexahydro-1,6-methanobenzo[c]azocine (MFG-1046)—



Iodotrimethylsilane (384 mg, 0.27 mL 1.92 mmol) was added in one portion to a solution of carbamate **2** (220 mg, 0.64 mmol) in CH_2Cl_2 (10.0 mL) at 0 °C in flask wrapped in foil. The cooling bath was removed after 2 h, and the reaction was stirred for an additional 3.25 h, whereupon the mixture was cooled to 0 °C, and methanolic HCl (2.0 M, 15 mL) was added. After stirring for 5 min, the volatiles were removed under reduced pressure, 2 N $HCl_{(aq)}$ (30 mL) was added, and the aqueous mixture was extracted with Et_2O (2 × 15 mL). The pH of the aqueous layer was adjusted to ~9 by the slow addition of 2.2 M $NaOH_{(aq)}$ and then extracted with CH_2Cl_2 (3 × 20 mL). The combined organic extracts were dried (Na_2SO_4), filtered, and concentrated under reduced pressure to afford 120 mg (90%) of the crude secondary amine which was of sufficient purity (>95% LC and ^{1}H NMR) to be used in the next step without purification. Cyclohexanecarboxaldehyde (**S8**, 47 mg, 50 μL, 0.42 mmol) was added to a solution of secondary amine (30 mg, 0.14 mmol) in DCE (1 mL), followed by the addition of sodium triacetoxyborohydride (88 mg, 0.42 mmol). The mixture was stirred for 24 h and then quenched by the addition of saturated sodium bicarbonate $solution_{(aq)}$. After stirring for 5 min, the layers were separated, and H_2O (~1 mL) was added and the resultant mixture extracted with CH_2Cl_2 (3 × 5 mL). Brine was added to the aqueous mixture, which was then extracted with CH_2Cl_2 (1 × 5 mL). The combined organic extracts

were dried ($MgSO_4$), filtered, and concentrated under reduced pressure to give the crude product, which was purified via flash column chromatography (SiO_2), eluting with 100% hexanes → 10% EtOAc/hexanes to afford 13 mg (30%) **MFG-1046** as a colorless oil: ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.36 (d, J = 10.0 Hz, 1 H), 7.26 (d, J = 10.0 Hz, 1 H), 7.20–7.16 (m, 1 H), 4.76–4.68 (m, 1 H), 3.39–3.34 (m, 1 H), 3.22–3.08 (m, 1 H), 2.83–2.58 (comp, 4 H), 2.41–2.30 (m, 1 H), 2.23–1.89 (comp, 5 H), 1.79–1.69 (comp, 2 H), 1.67–1.49 (comp, 4 H), 1.36–0.99 (comp, 4 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 151.9, 153.3, 133.1, 131.5, 126.4, 126.1, 67.1, 61.1, 51.8, 40.7, 34.4, 34.1, 32.3, 32.0, 30.0, 25.8, 25.6; IR (thin film) 2935, 2860, 1458 cm^{-1}; HRMS (ESI) m/z calcd for $C_{19}H_{27}ClN$ $(M+H)^+$, 304.18265; found, 304.18300.

(±)-Benzyl-9-(4-(trifluoromethyl)phenyl)-3,4,5,6-tetrahydro-1,6-methanobenzo[c]azocine-2(1H)-carboxylate (S10)—



A solution of carbamate **2** (258 mg, 0.75 mmol), 4-(trifluoromethyl)phenylboronic acid (286 mg, 1.5 mmol), Cs_2CO_3 (489 mg, 1.5 mmol), and palladium(bis)(*tert*-butyl)$_3$ phosphine (19 mg, 37 μmol) in degassed 1,4-dioxane (3.2 mL) was stirred for 1 min at room temperature and then 4 h at 98 °C. The reaction was cooled to room temperature and filtered through a pad of Celite, and the filter pad was rinsed with EtOAc (~30 mL). The combined filtrates were concentrated under reduced pressure, and the crude residue was purified via radial plc (SiO_2), eluting with 100% hexanes → 5% EtOAc/hexanes → 10% EtOAc/hexanes to give 299 mg **S10** (88%) as a white foam: ^{1}H NMR (500 MHz, $CDCl_3$, as a mixture of rotamers) δ 7.70–7.64 (m, 1 H), 7.61 (d, J = 10.0 Hz, 1 H), 7.53 (br s, 1 H), 7.52–7.42 (comp, 2 H), 7.39–7.31 (comp, 4 H), 7.23–7.20 (comp, 3), 5.66 (dd, J = 7.5 Hz, 0.4 H), 5.50 (dd, J = 7.5 Hz, 0.6 H), 5.37–5.29 (m, 1 H), 5.21–5.08 (m, 1 H), 4.21 (dd, J = 15.0, 5.0 Hz, 0.6 H), 3.93 (dd, J = 15.0, 5.0 Hz, 0.4 H), 3.50–3.45 (m, 1 H), 3.34–3.22 (m, 1 H), 2.46–2.34 (m, 1 H), 2.25–2.16 (m, 1 H), 1.95–1.85 (comp, 2 H), 1.65–1.55 (m, 1 H), 1.14–1.00 (m, 1 H); ^{13}C NMR (125 MHz, $CDCl_3$, mixture of rotamers) δ 155.7, 155.6, 147.1, 146.8, 146.7, 146.5, 144.7, 138.9, 138.7, 136.9, 136.7, 128.6, 128.5, 128.4, 128.2, 127.9, 127.8, 127.4, 127.2, 125.6 (q, $J_{C\text{-}F}$ = 3.75 Hz), 124.2, 124.0, 123.8, 123.3, 67.5, 67.2, 59.0, 58.3, 44.8, 44.2, 43.2, 43.0, 35.4, 35.3, 35.0, 34.9, 24.9, 24.7; IR (thin film) 2928, 1698, 1334 cm^{-1}; HRMS (ESI) m/z calcd for $C_{27}H_{24}F_3NNa_2O_2$ $(M+Na)^+$, 474.1651; found, 474.1657.

(±)-2-Cyclopentyl-9-(4-(trifluoromethyl)phenyl)-1,2,3,4,5,6-hexa-hydro-1,6-methanobenzo[c]azocine (DKR-1051)—



A mixture of **S10** (297 mg, 0.65 mmol) and 10% Pd/C (27 mg) in ethanol (10 mL) was stirred under an atmosphere of H_2 for five h. More 10% Pd/C (44 mg) was added, and the

reaction continued for an additional 3 h. The catalyst was removed by filtration through a cotton plug, and the combined filtrates were concentrated under reduced pressure to provide 208 mg (99%) of crude product, which was of sufficient purity (^{1}H NMR) to use in the subsequent reaction. Cyclopentanone (**S11**, 36 mg, 40 μL, 0.43 mmol) was added to a solution of secondary amine (69 mg, 0.21 mmol) in DCE (2.0 mL), and sodium triacetoxyborohydride (91 mg, 0.43 mmol) was added. The mixture was stirred for 24 h, and then saturated sodium bicarbonate solution$_{(aq)}$ (3 mL) was added. After stirring for 5 min, the layers were separated, H_2O was added (~1 mL), and the aqueous mixture was extracted with CH_2Cl_2 (3 × 5 mL). The combined organic extracts were dried ($MgSO_4$), filtered, and concentrated under reduced pressure to give the crude product, which was purified via radial plc (SiO_2), eluting with 10% EtOAc/hexanes → 15% EtOAc/hexanes to give 66 mg (79%; 78% over two steps) of **DKR-1051** as a colorless oil: ^{1}H NMR (500 MHz, $CDCl_3$) δ 7.72–7.65 (comp, 4 H), 7.54–7.45 (m, 1 H), 7.48 (d, J = 7.5 Hz, 1 H), 7.29 (d, J = 7.5 Hz, 1 H), 4.55–4.46 (m, 1 H), 3.37 (app t, J = 5.0 Hz, 1 H), 3.08–3.00 (m, 1 H), 2.82–2.73 (m, 1 H), 2.43–2.23 (comp, 2 H), 2.19–2.06 (comp, 2 H), 2.02–1.90 (comp, 2 H), 1.83–1.71 (comp, 4 H), 1.65–1.57 (comp, 4 H), 1.38–1.27 (m, 1 H); ^{13}C NMR (125 MHz, $CDCl_3$) δ 149.7, 145.1, 138.6, 129.1, 128.9, 127.4, 125.6 (q, $J_{C\text{-}F}$ = 3.75 Hz), 124.4, 123.9, 123.7, 123.3, 65.0, 63.5, 50.2, 42.3, 34.3, 32.9, 31.9, 30.7, 24.0; IR (thin film) 2963, 2866, 1623, 1327, 1128 cm^{-1}; HRMS (ESI) m/z calcd for $C_{24}H_{27}F_3N$ $(M+H)^+$, 386.2090; found 386.2092.

(±)-9-(4-(Trifluoromethyl)phenyl)-3,4,5,6-tetrahydro-1,6-methanobenzo[c]azocin-2(1H)-yl)propan-1-ol (UKH-1114)—



The benzyl carbamate of **S10** was removed with hydrogenolysis conditions as reported for the synthesis of **DKR-1051**. The secondary amine was of sufficient purity (^{1}H NMR) to use in the subsequent reaction. 3-Bromo-1-propanol (**S12**, 42 mg, 30 μL, 0.30 mmol) and K_2CO_3 (55 mg, 0.40 mmol) were added to a solution of secondary amine (32 mg, 0.10 mmol) in CH_3CN (2.0 mL), and the mixture was heated at 55 °C for 17 h. After cooling to room temperature, the solids were removed by filtration, and the filter cake was rinsed with CH_2Cl_2. The combined filtrates were concentrated under reduced pressure to give the crude product, which was purified via radial plc (SiO_2), eluting with 50% EtOAc/hexanes → 100% EtOAc → 3% MeOH/EtOAc to give 24 mg (64%; 63% over two steps) of **UKH-1114** as a colorless oil: ^{1}H NMR (400 MHz, CD_2Cl_2) δ 7.78–7.68 (comp, 4 H), 7.57 (s, 1 H), 7.53 (dd, J = 7.9, 1.8 Hz, 1 H), 7.33 (d, J = 7.9 Hz, 1 H), 4.41 (d, J = 5.6 Hz, 1 H), 3.93–3.82 (comp, 2 H), 3.38 (t, J = 6.2 Hz, 1 H), 3.01–2.92 (m, 1 H), 2.86–2.78 (m, 1 H), 2.63 (dd, J = 12.0, 8.4 Hz, 1 H), 2.24–2.11 (comp, 3 H), 2.04–1.94 (m, 1 H), 1.94–1.82 (m, 1 H), 1.78–1.65 (comp, 3 H), 1.42–1.30 (m, 1 H); ^{13}C NMR (150 MHz, $CDCl_3$) δ 144.6, 138.8, 129.4, 129.1, 128.3, 127.5, 125.7 (q, $J_{C\text{-}F}$ = 3.3 Hz), 125.2, 124.2, 124.1, 123.4, 66.5, 66.4, 50.3, 45.3, 41.5, 33.3, 27.9, 23.5, 22.3; IR (thin film) 3361, 2935, 2853, 1609, 1334, 1121 cm^{-1}; HRMS (ESI) m/z calcd for $C_{22}H_{25}F_3NO$ $(M+H)^+$, 376.1883; found 376.1892.

Sigma Receptor Binding Assay Protocol

Receptor binding assays were performed by the Psychoactive Drug Screening Program (PDSP) at Chapel Hill, North Carolina. The assay protocol book can be accessed free of charge at: https://pdspdb.unc.edu/pdspWeb/content/PDSP%20Protocols%20II%202013-03-28.pdf. Briefly, σ1R were sourced from guinea pig brain and Sig1R binding affinity (K_i) was determined through competition binding assays with [^{3}H]-(+)-pentazocine. σ2R were obtained from rat PC12 cells, and the Sig2R ligand binding affinity (K_i) was determined through competition binding assays using the radioligand [^{3}H]-ditolylguanidine in the presence of (+)-pentazocine to block σ1R binding sites. K_i values are calculated from best-fit IC_{50} determinations and are the average of two or more independent runs performed in triplicate.

Sample Preparation for in Vivo Use

Dry compounds were reconstituted in dimethyl sulfoxide (DMSO) to a stock concentration between 25 and 100 mM and then diluted down to 10 μg total drug in a volume of 5 μL for IT injections. The total amount of DMSO for IT injections was always less than 5%, and the vehicle injections always contained the same amount of DMSO. Siramesine (Tocris) sample was reconstituted and diluted in the same way. Samples were diluted in the same manner for IV injections.

Gene Expression Analysis

Transcripts per million (TPM) was used to quantify relative gene abundance. Fragments per kilobase of transcript per million mapped reads (FPKMs) for coding genes were obtained by running the Tophat/Cuffdiff[57] pipeline or from published data. These were then normalized to sum to 1 million in order to generate TPMs. For mouse single cell RNA-seq data sets, low sequencing depth makes TPMs inaccurate due to high sampling variation, and the fraction of cells with presence of sequenced reads from genes of interest for different cell types are presented instead.

Statistics

Data are shown as mean ± standard error of the mean, and the number of animals or samples used in each analysis are shown in figure legends. GraphPad Prism 7 for Mac OSX was used to analyze data. Two-way ANOVAs were used to analyze von Frey data with Bonferroni's multiple comparison post hoc test. Two tailed *t* tests were used to analyze rotorod data. Significance level was at $\alpha < 0.05$.

Acknowledgments

Funding

This work was supported by NIH grants R01NS065926 (T.J.P.) and R56NS098826 (T.J.P.), The University of Texas STARS program (T.J.P.), The Robert A. Welch Foundation (F-0652) (S.F.M.), and the Dell Medical School's Texas Health Catalyst program (S.F.M. and J.J.S.).

ABBREVIATIONS

σ1R	sigma 1 receptor
σ2R	sigma 2 receptor
AD	Alzheimer's disease
DRG	dorsal root ganglion
IT	intrathecal
IV	intravenous
MCI	mild cognitive impairment
SNI	spared nerve injury
TMEM97	transmembrane protein 97
TPM	transcripts per million mapped reads

References

1. Finnerup NB, Attal N, Haroutounian S, McNicol E, Baron R, Dworkin RH, Gilron I, Haanpaa M, Hansson P, Jensen TS, Kamerman PR, Lund K, Moore A, Raja SN, Rice AS, Rowbotham M, Sena E, Siddall P, Smith BH, Wallace M. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015; 14:162–173. [PubMed: 25575710]
2. Matsumoto, RR., Bown, WD., Su, TP. Sigma receptors: Chemistry, cell biology and clinical implications. Springer; New York: 2007.
3. Schmidt HR, Zheng S, Gurpinar E, Koehl A, Manglik A, Kruse AC. Crystal structure of the human sigma1 receptor. Nature. 2016; 532:527–530. [PubMed: 27042935]
4. Davis MP. Sigma-1 receptors and animal studies centered on pain and analgesia. Expert Opin. Drug Discovery. 2015; 10:885–900.
5. Gris G, Portillo-Salido E, Aubel B, Darbaky Y, Deseure K, Vela JM, Merlos M, Zamanillo D. The selective sigma-1 receptor antagonist E-52862 attenuates neuropathic pain of different aetiology in rats. Sci. Rep. 2016; 6:24591. [PubMed: 27087602]
6. Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, Kruse AC. Identification of the gene that codes for the sigma 2 receptor. Proc. Natl. Acad. Sci. U.S.A. 2017; doi: 10.1073/pnas.1705154114
7. Bartz F, Kern L, Erz D, Zhu M, Gilbert D, Meinhof T, Wirkner U, Erfle H, Muckenthaler M, Pepperkok R, Runz H. Identification of cholesterol-regulating genes by targeted RNAi screening. Cell Metab. 2009; 10:63–75. [PubMed: 19583955]
8. Sanchez-Pulido L, Ponting CP. TM6SF2 and MAC30, new enzyme homologs in sterol metabolism and common metabolic disease. Front. Genet. 2014; 5:439. [PubMed: 25566323]
9. Ebrahimi-Fakhari D, Wahlster L, Bartz F, Werenbeck-Ueding J, Praggastis M, Zhang J, Joggerst-Thomalla B, Theiss S, Grimm D, Ory DS, Runz H. Reduction of TMEM97 increases NPC1 protein levels and restores cholesterol trafficking in Niemann-pick type C1 disease cells. Hum. Mol. Genet. 2016; 25:3588–3599. [PubMed: 27378690]
10. Yi B, Sahn JJ, Ardestani PM, Evans AK, Scott LL, Chan JZ, Iyer S, Crisp A, Zuniga G, Pierce JT, Martin SF, Shamloo M. Small molecule modulator of sigma 2 receptor is neuroprotective and reduces cognitive deficits and neuroinflammation in experimental models of Alzheimer's disease. J. Neurochem. 2017; 140:561–575. [PubMed: 27926996]
11. Cahill MA. Progesterone receptor membrane component 1: an integrative review. J. Steroid Biochem. Mol. Biol. 2007; 105:16–36. [PubMed: 17583495]

12. Kabe Y, Nakane T, Koike I, Yamamoto T, Sugiura Y, Harada E, Sugase K, Shimamura T, Ohmura M, Muraoka K, Yamamoto A, Uchida T, Iwata S, Yamaguchi Y, Krayukhina E, Noda M, Handa H, Ishimori K, Uchiyama S, Kobayashi T, Suematsu M. Haem-dependent dimerization of PGRMC1/Sigma-2 receptor facilitates cancer proliferation and chemoresistance. Nat. Commun. 2016; 7:11030. [PubMed: 26988023]
13. Hand RA, Craven RJ. Hpr6.6 protein mediates cell death from oxidative damage in MCF-7 human breast cancer cells. J. Cell. Biochem. 2003; 90:534–547. [PubMed: 14523988]
14. Guo L, Zhen X. Sigma-2 receptor ligands: neurobiological effects. Curr. Med. Chem. 2015; 22:989–1003. [PubMed: 25620095]
15. Cognition Therapeutics. Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease, ClinicalTrials.gov Identifier: NCT02907567. 2016.
16. Minerva Neurosciences. Study to Evaluate the Efficacy, Safety, and Tolerability of MIN-101 in Patients With Negative Symptoms of Schizophrenia, EudraCT number: 2014-004878-42. 2014.
17. Sahn JJ, Hodges TR, Chan JZ, Martin SF. Norbenzomorphan Scaffold: Chemical Tool for Modulating Sigma Receptor-Subtype Selectivity. ACS Med. Chem. Lett. 2017; 8:455. [PubMed: 28435536]
18. Lipinski CA, Lombardo F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001; 46:3–26.
19. Veber DF, Johnson SR, Cheng HY, Smith BR, Ward KW, Kopple KD. Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. 2002; 45:2615–2623. [PubMed: 12036371]
20. Izzo NJ, Xu J, Zeng C, Kirk MJ, Mozzoni K, Silky C, Rehak C, Yurko R, Look G, Rishton G, Safferstein H, Cruchaga C, Goate A, Cahill MA, Arancio O, Mach RH, Craven R, Head E, LeVine H, Spires-Jones TL 3rd, Catalano SM. Alzheimer's therapeutics targeting amyloid beta 1–42 oligomers II: Sigma-2/PGRMC1 receptors mediate Abeta 42 oligomer binding and synaptotoxicity. PLoS One. 2014; 9:e111899. [PubMed: 25390692]
21. Roh DH, Kim HW, Yoon SY, Seo HS, Kwon YB, Kim KW, Han HJ, Beitz AJ, Na HS, Lee JH. Intrathecal injection of the sigma(1) receptor antagonist BD1047 blocks both mechanical allodynia and increases in spinal NR1 expression during the induction phase of rodent neuropathic pain. Anesthesiology. 2008; 109:879–889. [PubMed: 18946301]
22. de la Puente B, Nadal X, Portillo-Salido E, Sanchez-Arroyos R, Ovalle S, Palacios G, Muro A, Romero L, Entrena JM, Baeyens JM, Lopez-Garcia JA, Maldonado R, Zamanillo D, Vela JM. Sigma-1 receptors regulate activity-induced spinal sensitization and neuropathic pain after peripheral nerve injury. Pain. 2009; 145:294–303. [PubMed: 19505761]
23. Merlos M, Romero L, Zamanillo D, Plata-Salaman C, Vela JM. Sigma-1 Receptor and Pain. Handb. Exp. Pharmacol. 2017; doi: 10.1007/164_2017_9
24. Zhu S, Wang C, Han Y, Song C, Hu X, Liu Y. Sigma-1 Receptor Antagonist BD1047 Reduces Mechanical Allodynia in a Rat Model of Bone Cancer Pain through the Inhibition of Spinal NR1 Phosphorylation and Microglia Activation. Mediators Inflammation. 2015; 2015:265056.
25. Perregaard J, Moltzen EK, Meier E, Sanchez C. Sigma ligands with subnanomolar affinity and preference for the sigma 2 binding site. 1. 3-(omega-aminoalkyl)-1H–indoles. J. Med. Chem. 1995; 38:1998–2008. [PubMed: 7783131]
26. Abate C, Perrone R, Berardi F. Classes of sigma2 (sigma2) receptor ligands: structure affinity relationship (SAfiR) studies and antiproliferative activity. Curr. Pharm. Des. 2012; 18:938–949. [PubMed: 22288411]
27. Zeng C, Rothfuss JM, Zhang J, Vangveravong S, Chu W, Li S, Tu Z, Xu J, Mach RH. Functional assays to define agonists and antagonists of the sigma-2 receptor. Anal. Biochem. 2014; 448:68–74. [PubMed: 24333652]
28. Lonsdale J, Thomas J, Salvatore M, et al. GTEx Consortium. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 2013; 45:580–585. [PubMed: 23715323]
29. Dunham I, Kundaje A, Aldred SF, et al. The ENCODE Project Consortium. An integrated encyclopedia of DNA elements in the human genome. Nature. 2012; 489:57–74. [PubMed: 22955616]

30. Uhlen M, Fagerberg L, Hallstrom BM, Lindskog C, Oksvold P, Mardinoglu A, Sivertsson Å, Kampf C, Sjostedt E, Asplund A, et al. Tissue-based map of the human proteome. Science. 2015; 347:1260419. [PubMed: 25613900]

31. Duff MO, Olson S, Wei X, Garrett SC, Osman A, Bolisetty M, Plocik A, Celniker SE, Graveley BR. Genome-wide identification of zero nucleotide recursive splicing in Drosophila. Nature. 2015; 521:376–379. [PubMed: 25970244]

32. Davidson S, Golden JP, Copits BA, Ray PR, Vogt SK, Valtcheva MV, Schmidt RE, Ghetti A, Price TJ, Gereau RW IV. Group II mGluRs suppress hyperexcitability in mouse and human nociceptors. Pain. 2016; 157:2081–2088. [PubMed: 27218869]

33. Gilad Y, Mizrahi-Man O. A reanalysis of mouse ENCODE comparative gene expression data. F1000Research. 2015; 4:121. [PubMed: 26236466]

34. Benoit J, Ayoub AE, Rakic P. Transcriptomics of critical period of visual cortical plasticity in mice. Proc. Natl. Acad. Sci. U. S. A. 2015; 112:8094–8099. [PubMed: 26080443]

35. Gerhold KA, Pellegrino M, Tsunozaki M, Morita T, Leitch DB, Tsuruda PR, Brem RB, Catania KC, Bautista DM. The star-nosed mole reveals clues to the molecular basis of mammalian touch. PLoS One. 2013; 8:e55001. [PubMed: 23383028]

36. Eipper-Mains JE, Kiraly DD, Duff MO, Horowitz MJ, McManus CJ, Eipper BA, Graveley BR, Mains RE. Effects of cocaine and withdrawal on the mouse nucleus accumbens transcriptome. Genes, Brain and behavior. 2013; 12:21–33.

37. Huan T, Meng Q, Saleh MA, Norlander AE, Joehanes R, Zhu J, Chen BH, Zhang B, Johnson AD, Ying S, et al. Integrative network analysis reveals molecular mechanisms of blood pressure regulation. Mol. Syst. Biol. 2015; 11:799. [PubMed: 25882670]

38. Usoskin D, Furlan A, Islam S, Abdo H, Lonnerberg P, Lou D, Hjerling-Leffler J, Haeggstrom J, Kharchenko O, Kharchenko PV, et al. Unbiased classification of sensory neuron types by large-scale single-cell RNA sequencing. Nat. Neurosci. 2015; 18:145–153. [PubMed: 25420068]

39. Zhang Y, Chen K, Sloan SA, Bennett ML, Scholze AR, O'Keeffe S, Phatnani HP, Guarnieri P, Caneda C, Ruderisch N, et al. An RNA-sequencing transcriptome and splicing database of glia, neurons, and vascular cells of the cerebral cortex. J. Neurosci. 2014; 34:11929–11947. [PubMed: 25186741]

40. Romero L, Zamanillo D, Nadal X, Sanchez-Arroyos R, Rivera-Arconada I, Dordal A, Montero A, Muro A, Bura A, Segales C, Laloya M, Hernandez E, Portillo-Salido E, Escriche M, Codony X, Encina G, Burgueno J, Merlos M, Baeyens JM, Giraldo J, Lopez-Garcia JA, Maldonado R, Plata-Salaman CR, Vela JM. Pharmacological properties of S1RA, a new sigma-1 receptor antagonist that inhibits neuropathic pain and activity-induced spinal sensitization. Br. J. Pharmacol. 2012; 166:2289–2306. [PubMed: 22404321]

41. Ji RR, Chamessian A, Zhang YQ. Pain regulation by non-neuronal cells and inflammation. Science. 2016; 354:572–577. [PubMed: 27811267]

42. Nieto FR, Cendan CM, Sanchez-Fernandez C, Cobos EJ, Entrena JM, Tejada MA, Zamanillo D, Vela JM, Baeyens JM. Role of sigma-1 receptors in paclitaxel-induced neuropathic pain in mice. J. Pain. 2012; 13:1107–1121. [PubMed: 23063344]

43. Diaz JL, Cuberes R, Berrocal J, Contijoch M, Christmann U, Fernandez A, Port A, Holenz J, Buschmann H, Laggner C, Serafini MT, Burgueno J, Zamanillo D, Merlos M, Vela JM, Almansa C. Synthesis and biological evaluation of the 1-arylpyrazole class of sigma(1) receptor antagonists: identification of 4-{2-[5-methyl-1-(naphthalen-2-yl)-1H–pyrazol-3-yloxy]ethyl}-morpholine (S1RA, E-52862). J. Med. Chem. 2012; 55:8211–8224. [PubMed: 22784008]

44. Mavlyutov TA, Duellman T, Kim HT, Epstein ML, Leese C, Davletov BA, Yang J. Sigma-1 receptor expression in the dorsal root ganglion: Reexamination using a highly specific antibody. Neuroscience. 2016; 331:148–157. [PubMed: 27339730]

45. Qiu G, Sun W, Zou Y, Cai Z, Wang P, Lin X, Huang J, Jiang L, Ding X, Hu G. RNA interference against TMEM97 inhibits cell proliferation, migration, and invasion in glioma cells. Tumor Biol. 2015; 36:8231–8238.

46. Asiedu MN, Tillu DV, Melemedjian OK, Shy A, Sanoja R, Bodell B, Ghosh S, Porreca F, Price TJ. Spinal protein kinase M zeta underlies the maintenance mechanism of persistent nociceptive sensitization. J. Neurosci. 2011; 31:6646–6653. [PubMed: 21543593]

47. Melemedjian OK, Asiedu MN, Tillu DV, Sanoja R, Yan J, Lark A, Khoutorsky A, Johnson J, Peebles KA, Lepow T, Sonenberg N, Dussor G, Price TJ. Targeting adenosine monophosphate-activated protein kinase (AMPK) in preclinical models reveals a potential mechanism for the treatment of neuropathic pain. Mol. Pain. 2011; 7:70. [PubMed: 21936900]

48. Melemedjian OK, Khoutorsky A, Sorge RE, Yan J, Asiedu MN, Valdez A, Ghosh S, Dussor G, Mogil JS, Sonenberg N, Price TJ. mTORC1 inhibition induces pain via IRS-1-dependent feedback activation of ERK. Pain. 2013; 154:1080–1091. [PubMed: 23607966]

49. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL. Quantitative assessment of tactile allodynia in the rat paw. J. Neurosci. Methods. 1994; 53:55–63. [PubMed: 7990513]

50. Decosterd I, Woolf CJ. Spared nerve injury: an animal model of persistent peripheral neuropathic pain. Pain. 2000; 87:149–158. [PubMed: 10924808]

51. Hylden JL, Wilcox GL. Intrathecal morphine in mice: a new technique. Eur. J. Pharmacol. 1980; 67:313–316. [PubMed: 6893963]

52. Pangborn AB, Giardello MA, Grubbs RH, Rosen RK, Timmers FJ. Safe and convenient procedure for solvent purification. Organometallics. 1996; 15:1518–1520.

53. Still WC, Kahn M, Mitra A. Rapid Chromatographic Technique for Preparative Separations with Moderate Resolution. J. Org. Chem. 1978; 43:2923–2925.

54. Sahn JJ, Martin SF. Expedient synthesis of norbenzomorphan library via multicomponent assembly process coupled with ring-closing reactions. ACS Comb. Sci. 2012; 14:496–502. [PubMed: 22857149]

55. Sahn JJ, Hodges TR, Chan JZ, Martin SF. Norbenzomorphan Framework as a Novel Scaffold for Generating Sigma 2 Receptor/PGRMC1 Subtype-Selective Ligands. ChemMed-Chem. 2016; 11:556–561.

56. Sahn JJ, Martin SF. Facile Syntheses of Substituted, Conformationally-Constrained Benzoxazocines and Benzazocines via Sequential Multicomponent Assembly and Cyclization. Tetrahedron Lett. 2011; 52:6855–6858. [PubMed: 22711939]

57. Trapnell C, Roberts A, Goff L, Pertea G, Kim D, Kelley DR, Pimentel H, Salzberg SL, Rinn JL, Pachter L. Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks. Nat. Protoc. 2012; 7:562–578. [PubMed: 22383036]



Figure 1.

Norbenzomorphan and methanobenzazocine scaffolds **1** and **2** and the CNS penetrant σ2R/Tmem97 ligands **SAS-0132** and **DKR-1051**.



Figure 2.

σ Receptor binding ligands.[a] K_i are shown for each ligand at σ1R or σ2R/Tmem97 as the mean of at least two independent experiments ± standard deviation. Siramesine data is from ref 25. [a]For all compounds, σ2R/Tmem97 was sourced from rat PC12 cells, with the exception of siramesine, which utilized rat brain homogentate. See Methods Section for more details.



Figure 3.

Effect of IT injection of σ1R ligands in the mouse SNI model. Compounds acting on σ1R were tested in the mouse SNI model. Mechanical sensitivity was measured at the indicated time points after IT injection of 10 μg compound. All vehicle groups, $n = 6$; **JWG-1014**, $n = 5$; **JSS-1027**, $n = 5$; **MFG-1046**, $n = 4$. $^{**}p < 0.01$, $^{***}p < 0.001$, and $^{****}p < 0.0001$.



Figure 4.

Effect of IT injection of σ2R/Tmem97 ligands in the SNI model. Mechanical sensitivity was measured at the indicated time points after IT injection of 10 μg compound. (A) Effect of siramesine ($n = 4$) compared to vehicle ($n = 6$) is shown. (B) Effect of **DKR-1005** ($n = 6$), **DKR-1051** ($n = 5$) and **UKH-1114** ($n = 11$) compared to vehicle ($n = 6$) is shown. *$p <$ 0.05, **$p < 0.01$, ***$p < 0.001$, and ****$p < 0.0001$.



Figure 5.

Effect of **UKH-1114** is blocked by the σ2R/Tmem97 antagonist **SAS-0132**. σ2R/Tmem antagonist **SAS-0132** at 10 μg dose given at the same time as **UKH-1114**, also at 10 μg dose, completely blocked the effect seen with **UKH-1114** given alone. $n = 6$ per group. ****$p <$ 0.0001.



Figure 6.

Systemic dosing with **UKH-1114** leads to alleviation of neuropathic pain without motor effects. (A) Vehicle ($n = 6$), gabapentin (100 mg/kg, $n = 6$), or **UKH-1114** (10 mg/kg, $n = 6$) were given IV and mechanical testing was done at the indicated time points. (B) Rotorod testing was done 48 h after IV injection on an accelerating rotorod reaching a maximum of 40 rotations per minute over 200 s. Latency to fall is shown on the third trial ($n = 6$ per group). ****$p < 0.0001$.





Neuronal subpopulations in adult mouse DRG

Subtypes	Neurofilament					Non-peptidergic			Peptidergic		TH +ve
Subclusters	NF1	NF2/3		NF4/5		NP1	NP2/3		PEP1	PEP2	TH1
		NF2	NF3	NF4	NF5		NP2	NP3			
No of cells	31	48	12	22	26	125	32	12	64	17	233
Nefh	81%	96%	92%	73%	100%	1%	0%	0%	13%	65%	1%
P2rx3	3%	0%	17%	0%	0%	86%	47%	58%	16%	35%	10%
Th	0%	2%	0%	0%	0%	0%	0%	0%	2%	0%	67%
Calca	0%	0%	8%	0%	0%	20%	88%	8%	78%	100%	1%
Tmem97	**10%**	**8%**	**0%**	**14%**	**0%**	**26%**	**6%**	**8%**	**6%**	**29%**	**9%**

Fraction of cells with detectable expression

Cell types in adult mouse cerebral cortex

	Neural	Glial					
		Oligodendrocytes					
	Neuron	Astrocytes	Precursor	Newly Formed	Myelinating	Microglia	Endothelial Cells
Rbfox3/NeuN	86.2	1.2	11.6	1.5	7.3	6.6	1.7
Tmem97	**26.8**	**65.4**	**50.7**	**33.2**	**45.3**	**39.8**	**17.6**

Coding gene relative abundance (in TPMs)

Figure 7.

Expression analysis for *Tmem97* (A), *TMEM97* (human), and *Tmem97* (mouse) gene expression across orthologous tissues, with greater expression in the mouse and human GI tract and the human DRG. (B) Analysis of mouse single cell data reveals a maximum detection rate of 29% for *Tmem97* across all sensory neuron subpopulations as contrasted with 67% or more for known subpopulation marker genes. (C) Cortical expression of *Tmem97* as contrasted with the neuronal marker NeuN. *Tmem97* expression spans both neuronal and non-neuronal cells, with ~1.5–2.5-fold higher expression in non-neuronal cells.



Figure 8.

Synthesis of norbenzomorphan σ2R/Tmem97 ligands.

Reagents and conditions (a) 10% Pd/C, H_2, EtOH. (b) K_2CO_3, CH_3CN, 50 °C. (c) $Pd(OAc)_2$, JohnPhos®, NaO*t*-Bu, toluene, 100 °C. (d) TMSI, CH_2Cl_2, then HCl. (e) $Na(OAc)_3BH$, CH_3COOH, 1,2-dichloroethane.



Figure 9.

Synthesis of methanobenzazocine σ2R/Tmem97 ligands.

Reagents and conditions (a) TMSI, CH_2Cl_2, then HCl. (b) $Na(OAc)_3BH$, 1,2-dichloroethane. (c) $Pd[P(^tBu)_3]_2$, Cs_2CO_3, 1,4-dioxane, 98 °C. (d) 10% Pd/C, H_2, EtOH. (e) K_2CO_3, CH_3CN, 55 °C.

Table 1

Chemical Properties of UKH-1114[a]

molecular weight	375.4
ClogD (7.4)	4.3
total polar surface area	23.5
hydrogen bond donors	1
hydrogen bond acceptors	2
rotatable bonds	5

[a]Calculated with ACD/I-Laboratories (https://ilab.acdlabs.com/iLab2/).

Table 2

UKH-1114 Binding Profile at Non-Sigma Receptor Sites

target	K_i (nM)	target	K_i (nM)
$5HT_{1A}$	*a*	Beta2	*a*
$5HT_{1B}$	*a*	Beta3	*a*
$5HT_{1D}$	*a*	BZP rat brain	*a*
$5HT_{1e}$	*a*	calcium channel	>10 000
$5HT_{2A}$	*a*	D_1	*a*
$5HT_{2B}$	*a*	D_2	*a*
$5HT_{2C}$	*a*	D_3	*a*
$5HT_3$	*a*	D_4	*a*
$5HT_{5a}$	*a*	D_5	*a*
$5HT_6$	*a*	DOR	*a*
$5HT_7$	*a*	GabaA	*a*
A2B2	*a*	H_1	*a*
A2B4	*a*	H_3	*a*
A3B2	*a*	KOR	1383
A3B4	*a*	M_1	*a*
A4B2	*a*	M_2	*a*
A4B2[b]	*a*	M_3	*a*
A4B4	*a*	M_4	*a*
A7	*a*	M_5	*a*
A7[b]	*a*	MOR	*a*
$Alpha_{1a}$	*a*	NET	1046
$Alpha_{1b}$	*a*	NMDA	6724
$Alpha_{1d}$	*a*	PBR	*a*
$Alpha_{2a}$	*a*	SERT	*a*
$Alpha_{2b}$	*a*	V1A	>10 000
$Alpha_{1c}$	*a*	V1B	>10 000
AMPA	>10 000	V2	>10 000
Beta1	*a*		

[a] <50% inhibition of radioligand binding at 10 μM.

[b] Sourced from rodent brain.